AMS to licence Delmopinol from Sinclair IS Pharma
For worldwide use in foam-based woundcare dressings
Woundcare firm Advanced Medical Solutions (AMS) has signed a licensing agreement with London-based Sinclair IS Pharma.
AMS, a global medical technology company headquartered in Winsford, Cheshire in the UK, has secured the right exclusively to licence Delmopinol from Sinclair IS for worldwide use in foam-based woundcare dressings.
Delmopinol is the active ingredient in Decapinol, Sinclair IS’s oral healthcare products, where it has proven to be effective as an anti-biofilm agent. Bacterial biofilms are widely recognised as a major cause of microbial resistance to current treatments.
AMS has already evaluated the efficacy of Delmopinol with several universities in a number of in vitro models to assess its potential in combination with an AMS anti-microbial woundcare dressing.
Under the agreement AMS will now conduct further r&d and feasibility testing for up six months.
Chris Meredith, chief executive of AMS, said: ‘We believe the future of advanced woundcare lies in antimicrobial and ‘active’ wound dressings. In this regard, our r&d programme has been looking into ways to control biofilms within chronic wounds to further improve the efficacy of our dressings.
‘Whilst there is still work to do to confirm its feasibility, indications so far are encouraging that a combination of Delmopinol and our own anti-microbial foam technologies could provide an effective new range of dressings to combat biofilms.’
